Clinical implications of FDG PETCT in cancer of unknown primaries
Cancer of unknown primary (CUP) has an incidence of 3.3% in the UK but this is falling, largely due to improvement in diagnostics, enabling underlying pathology to be identified and treated, therefore improving survival outcomes. F-18 FDG PETCT is increasingly being used to investigate for malignancy in patients in whom initial tests have proven inconclusive and is recommended by NICE for patients with cervical lymphadenopathy and suspicion of CUP with no primary identified on ENT endoscopy, or in patients with extra cervical presentation following discussion with the CUP team.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.